ReviewFEBS letters2025
Goodbye flat lymphoma biology.
Review in FEBS letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Why antibody isotype matters for immunotherapy.Antibody therapeutics · 2026Review
- 3D ex vivo platform for high-throughput immunotherapy screening in relapsed/refractory lymphoma patients.HemaSphere · 2026Article
- Matrix Stiffness Regulates Diffuse Large B-Cell Lymphoma (DLBCL) Spheroid Formation in a Tunable 3D Chitosan Hydrogel Model.Gels (Basel, Switzerland) · 2026Article
- The B-cell Receptor Blueprint in Lymphoma: Mechanisms and Therapeutic Opportunities.Blood cancer discovery · 2026Review
- Developing a 3D Model Culture of an EBV+/CD30+ B-Anaplastic Large Cell Lymphoma Cell Line to Assay Brentuximab Vedotin Treatment.Antibodies (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
B-cell lymphomas grow in aggregates, closely interacting with specific physical elements and cellular environments. While 2D culture systems have long been the standard in the field, current methodologies aim to better replicate lymphoma biology and its microenvironment in 3D. Significant progress has been made since the first 3D lymphoma cell line culture was developed in 2012. Subsequent advances in both cell line and patient-derived systems have incorporated key physical and cellular microenvironmental components. This Review compiles the relevant 3D non-Hodgkin lymphoma models available, outlining their main features, strengths, and limitations. Additionally, we highlight the critical gaps that must be addressed to develop robust, multiplexed, patient-derived B-cell lymphoma systems, which can serve as reliable avatars alongside clinical trials and contribute to the principles of the 3Rs in animal research. Impact statement In the last few years new B-cell lymphoma 3D models have emerged, with a special emphasis on patient-derived models. These systems are fundamental tools for precision medicine. This review provides translational researchers and clinician scientists with an excellent overview of these novel tools with their strong and weak points.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.